You just read:

New Phase 3 Monotherapy Study of Sirukumab Versus Humira® and Sirukumab Data in an Anti-TNF Refractory Population Reported in the Treatment of Moderately to Severely Active Rheumatoid Arthritis

News provided by

Janssen Immunology

16 Nov, 2016, 16:46 GMT